Stability of sulforaphane for topical formulation

被引:49
|
作者
Franklin, Stephen J. [1 ]
Dickinson, Sally E. [2 ]
Karlage, Kelly L. [1 ]
Bowden, G. T. [3 ]
Myrdal, Paul B. [1 ]
机构
[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[2] Univ Arizona, Ctr Canc, Dept Pharmacol, Tucson, AZ 85721 USA
[3] Univ Arizona, Ctr Canc, Dept Cellular & Mol Med, Tucson, AZ 85721 USA
关键词
Activator-protein-1; base catalysis; degradation; hydrolysis; in vivo; isothiocyanate; UVB; INDUCED ACTIVATOR PROTEIN-1; BROCCOLI SPROUT EXTRACTS; HAIRLESS MOUSE MODEL; PERILLYL ALCOHOL; SKIN-CANCER; INHIBITION; AP-1; CHEMOPREVENTION; EXPRESSION;
D O I
10.3109/03639045.2013.768634
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Context: Sulforaphane (SFN) is a natural compound that has been investigated as a chemopreventive agent. SFN has been shown to inhibit the activator-protein-1 (AP-1) transcription factor and may be effective for inhibition of ultraviolet (UV) induced skin carcinogenesis. This study was designed to investigate the stability of SFN as a function of pH, temperature and in various solvents and formulations. Materials and methods: Stability was analyzed using high-performance liquid chromatography. A potential lead formulation was identified and evaluated in vivo. Results: SFN was determined to undergo apparent first-order degradation kinetics for the conditions explored. It was observed that SFN undergoes base catalyzed degradation. Buffer species and solvent type impacts stability as well. SFN was found to be very sensitive to temperature with degradation rate changing by a factor of nearly 3.1 for every 10 degrees C change in temperature (at pH 4.0). SFN completely degraded after 30 days in a conventional pharmaceutical cream formulation. Improved stability was observed in organic formulation components. Stability studies were conducted on two nonaqueous topical formulations: a polyethylene glycol (PEG) ointment base and an organic oleaginous base. Conclusion: Topically applied SFN in the PEG base formulation significantly reduced AP-1 activation after UV stimulation in the skin of a transgenic mouse model, indicating that SFN in this formulation retains efficacy in vivo.
引用
收藏
页码:494 / 502
页数:9
相关论文
共 50 条
  • [31] Formulation of Tacrolimus in topical Dosage Forms
    Pfaller, Anna
    Melchior, Kai
    Vaghela, Nilesh
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 86 - 87
  • [32] Formulation, pharmacokinetics and pharmacodynamics of topical microbicides
    Adams, Jessica L.
    Kashuba, Angela D. M.
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2012, 26 (04) : 451 - 462
  • [33] Formulation of Dry Emulsion for Topical Applications
    Gallarate, Marina
    Mittone, Elena
    Carlotti, M. Eugenia
    Trotta, Michele
    Piccerelle, Philippe
    JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY, 2009, 30 (06) : 823 - 833
  • [34] Formulation of liposome for topical delivery of arbutin
    Wen, Ai-Hua
    Choi, Min-Koo
    Kim, Dae-Duk
    ARCHIVES OF PHARMACAL RESEARCH, 2006, 29 (12) : 1187 - 1192
  • [35] EXTEMPORANEOUS FORMULATION OF CORTICOSTEROIDS FOR TOPICAL USAGE
    BURDICK, KH
    POULSEN, B
    PLACE, VA
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1970, 211 (03): : 462 - &
  • [36] EXTEMPORANEOUS FORMULATION OF TOPICAL STEROIDS - REPLY
    BURDICK, KH
    POULSEN, B
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1970, 212 (11) : 1963 - +
  • [37] Topical Nanoemmigel Formulation of Boswellia serrata
    Kathpalia, H.
    Shreya, K. K.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 80 (02) : 261 - 267
  • [38] Formulation studies on topical preparations of clonazepam
    Mura, P
    Faucci, MT
    Corti, P
    Bramanti, G
    STP PHARMA SCIENCES, 1997, 7 (03): : 229 - 234
  • [39] Method Development, Stability, and Pharmacokinetic Studies of Acyclovir-Loaded Topical Formulation in Spiked Rat Plasma
    Alqahtani, Safar M.
    Altharawi, Ali
    Altamimi, Mohammad A.
    Alossaimi, Manal A.
    Mahdi, Wael A.
    Ramzan, Mohhammad
    Hussain, Afzal
    PROCESSES, 2022, 10 (10)
  • [40] Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
    Clara Cortell-Fuster
    María Amparo Martínez-Gómez
    Ana Cristina Cercós-Lleti
    Mónica Climente-Martí
    Journal of Pharmaceutical Innovation, 2023, 18 : 2287 - 2293